Disc Medicine Inc

NASDAQ: IRON
$65.00
+$1.67 (+2.6%)
Closing Price on November 8, 2024

IRON Stock Chart and Intraday Price

IRON Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address C/O FORESITE CAPITAL, 600 MONTGOMERY ST, SUITE 4500, SAN FRANCISCO, CA, US
Fiscal Year End December
Latest Quarter 9/30/2023
Market Cap 1,818.26M USD
Shares Outstanding 24,140,400
Disc Medicine, Inc., together with its subsidiaries, operates as a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and MWTX-003 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. The company was founded in 2017 and is headquartered in Watertown, Massachusetts.

IRON Articles

Warren Buffett has purchased more of his favorite energy stock. A couple of biotech stocks and a recreational boat maker also saw sizable buys from insiders.
Monday's top analyst upgrades and downgrades included Activision Blizzard, Adobe, Caesars Entertainment, Corning, DocuSign, Park Hotels & Resorts, PayPal, Target, Trip.com, Twilio and UiPath.